Glutamate Receptor Gene Variants Linked to Comorbid ADHD and Autism

Large-scale genomic analysis identifies specific structural variants in glutamatergic networks that distinguish complex ADHD phenotypes.

For Doctors in a Hurry

Researchers investigated whether copy number variants in glutamate receptor networks contribute to the clinical complexity of ADHD with comorbid neurodevelopmental disorders.
This study analyzed genetic data from 72,626 pediatric participants, including 12,472 individuals diagnosed with attention-deficit hyperactivity disorder.
Twenty-seven genes within the glutamate receptor network showed significant enrichment of copy number variants in comorbid cases (FDR < 0.05).
The findings indicate that ADHD with comorbid conditions possesses a distinct genetic profile involving disrupted glutamatergic signaling pathways.
These results suggest that identifying glutamate network disruptions could facilitate genetically informed interventions for patients with complex neurodevelopmental phenotypes.

The Molecular Architecture of Complex Neurodevelopmental Phenotypes

Neurodevelopmental disorders such as attention-deficit hyperactivity disorder (ADHD) and autism spectrum disorder typically manifest early, with a peak age at onset of 5.5 years [1]. Clinicians are increasingly managing patients who present with significant phenotypic overlap, where diagnostic lines blur. This clinical complexity is reflected in systemic associations, such as the link between atopic dermatitis and neurodevelopmental conditions, which carries a pooled odds ratio of 1.28 for ADHD and 1.87 for autism spectrum disorder [2]. These multifaceted presentations contribute to a substantial global burden of pediatric disability, with mental disorders accounting for 125.3 million disability-adjusted life-years (a measure of overall disease burden) as of 2019 [3]. While recent genomic analyses have identified 102 risk genes for developmental disorders [4], the specific molecular factors that distinguish complex, comorbid cases from single-diagnosis presentations have remained poorly defined, posing a challenge for precise diagnosis and prognosis.

Large-Scale Genomic Screening of Pediatric ADHD Cohorts

To investigate the genetic architecture of these complex phenotypes, researchers conducted a large-scale genomic analysis of 72,626 pediatric participants from the Center for Applied Genomics at Children’s Hospital of Philadelphia. The cohort included 12,472 individuals with ADHD, of whom 7,967 also had comorbid neurodevelopmental conditions such as autism spectrum disorder, anxiety, or developmental delay. This stratification enabled a direct comparison of the genetic profiles of patients with isolated ADHD versus those with more complex clinical presentations. The investigators focused on identifying copy number variants (CNVs), which are deletions or duplications of DNA segments that can alter gene function. Using a computational tool called PennCNV, they scanned each participant's genome for these structural variations, specifically looking for those affecting metabotropic glutamate receptor (GRM) genes, which are crucial for modulating neuronal excitability. To understand the broader biological impact, the team used the STRING database to map how these affected genes fit within larger protein-protein interaction networks, essentially creating a circuit diagram of the glutamatergic signaling system. This network-based approach allowed the analysis to move beyond single genes to assess the cumulative burden of genetic disruption within a key neurodevelopmental pathway, comparing the findings across the comorbid ADHD, ADHD-only, and disease-free control groups.

Enrichment of Glutamatergic Signaling Networks

The analysis revealed a distinct genetic signature in patients with complex neurodevelopmental profiles. While prior work has linked copy number variants in metabotropic glutamate receptor (GRM) genes to both ADHD and autism spectrum disorder, this study found a significant enrichment of CNVs within the broader GRM interaction network specifically among individuals with ADHD and comorbid conditions. This suggests that the integrity of the entire glutamatergic signaling pathway, not just the core receptor genes, is a critical factor in determining clinical complexity. The researchers identified 27 specific genes that interact with GRM genes and were disproportionately affected by CNVs in the comorbid group, a finding that met a stringent statistical threshold with a false discovery rate (FDR) of less than 0.05. This statistical method controls for the high probability of false positives when conducting many genetic comparisons simultaneously. In stark contrast, the enrichment of these same CNVs in the ADHD-only group was notably less. For the practicing clinician, these data suggest that patients presenting with ADHD alongside anxiety, autism, or developmental delay may harbor a greater burden of genetic disruption in glutamatergic pathways, distinguishing them biologically from patients with uncomplicated ADHD.

Molecular Drivers of Clinical Complexity

Delving deeper into the affected pathways, the study highlighted several key neurodevelopmental genes driving this genetic enrichment, including DLG2, NRXN1, SHANK3, and SYNGAP1. These genes are well-known for their roles in synaptic function, particularly in building the molecular scaffold that supports glutamatergic neurotransmission, the brain's primary excitatory signaling system. Disruptions to these specific genes, which are critical for synaptic plasticity and stability, can impair how neurons communicate and form lasting connections. The findings demonstrate that ADHD cases with comorbid neurodevelopmental disorders exhibit a distinct genetic profile marked by a higher mutational load in these essential synaptic components. The authors conclude that disruptions across the metabotropic glutamate receptor network contribute directly to the phenotypic complexity observed in patients with ADHD and co-occurring conditions. This evidence provides a molecular basis for the clinical observation that these multifaceted cases are often more severe, suggesting that the underlying pathology involves a more widespread disturbance of excitatory signaling in the brain.

Clinical Implications for Targeted Intervention

The management of pediatric patients with complex neurodevelopmental profiles is often challenging due to the absence of clear biological markers to guide treatment. This study helps to fill that gap by identifying a specific genetic vulnerability in a large patient cohort. The finding that 27 genes within the metabotropic glutamate receptor (GRM) network are significantly enriched in copy number variants (FDR < 0.05) among patients with ADHD and comorbid conditions provides a potential biomarker for this high-complexity group. This molecular signature suggests that the co-occurrence of conditions like anxiety or autism spectrum disorder with ADHD is not a random clinical association but is linked to a higher burden of genetic disruption in glutamatergic signaling pathways. For clinicians, these results point toward a potential pathway for genetically informed interventions. While standard ADHD therapies primarily target catecholamine systems, this research highlights the glutamate system as a distinct therapeutic target for a subset of patients. Identifying disruptions in genes like SHANK3 and SYNGAP1 could eventually allow for a more precise stratification of patients, guiding the use of agents that modulate glutamatergic function. This approach offers a path toward tailoring therapies to a patient's underlying genetic architecture, potentially improving outcomes for children with the most complex neurodevelopmental needs.

Study Info

Targeting glutamatergic pathways: genetic insights into comorbid neurodevelopmental disorders

Joseph T Glessner, Munir E Khan, Xiao Chang, Yichuan Liu, et al.

Journal Brain

Published May 07, 2026